Utah Retirement Systems grew its stake in bluebird bio Inc (NASDAQ:BLUE) by 8.6% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 10,100 shares of the biotechnology company’s stock after acquiring an additional 800 shares during the quarter. Utah Retirement Systems’ holdings in bluebird bio were worth $1,475,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently modified their holdings of BLUE. FMR LLC increased its stake in shares of bluebird bio by 8.1% in the 3rd quarter. FMR LLC now owns 8,123,687 shares of the biotechnology company’s stock worth $1,186,058,000 after acquiring an additional 605,797 shares during the last quarter. Bank of New York Mellon Corp increased its stake in shares of bluebird bio by 86.1% in the 3rd quarter. Bank of New York Mellon Corp now owns 581,695 shares of the biotechnology company’s stock worth $84,926,000 after acquiring an additional 269,074 shares during the last quarter. First Trust Advisors LP increased its stake in shares of bluebird bio by 63.2% in the 3rd quarter. First Trust Advisors LP now owns 601,883 shares of the biotechnology company’s stock worth $87,875,000 after acquiring an additional 233,175 shares during the last quarter. BlackRock Inc. increased its stake in shares of bluebird bio by 7.9% in the 3rd quarter. BlackRock Inc. now owns 2,952,089 shares of the biotechnology company’s stock worth $431,005,000 after acquiring an additional 216,914 shares during the last quarter. Finally, Commerzbank Aktiengesellschaft FI increased its stake in shares of bluebird bio by 104.5% in the 2nd quarter. Commerzbank Aktiengesellschaft FI now owns 7,958 shares of the biotechnology company’s stock worth $1,249,000 after acquiring an additional 183,590 shares during the last quarter.
In related news, Director James Mandell sold 1,000 shares of the firm’s stock in a transaction dated Monday, September 10th. The stock was sold at an average price of $150.77, for a total transaction of $150,770.00. Following the completion of the transaction, the director now directly owns 1,568 shares in the company, valued at approximately $236,407.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Susanna Gatti High sold 1,890 shares of the firm’s stock in a transaction dated Monday, December 3rd. The shares were sold at an average price of $113.83, for a total value of $215,138.70. Following the transaction, the chief operating officer now owns 15,610 shares of the company’s stock, valued at $1,776,886.30. The disclosure for this sale can be found here. Insiders have sold a total of 21,490 shares of company stock valued at $2,901,186 over the last 90 days. 3.00% of the stock is currently owned by company insiders.
A number of brokerages have issued reports on BLUE. BidaskClub raised bluebird bio from a “strong sell” rating to a “sell” rating in a research note on Friday, November 30th. Zacks Investment Research downgraded bluebird bio from a “buy” rating to a “hold” rating in a research report on Friday, November 30th. William Blair reissued a “buy” rating on shares of bluebird bio in a research report on Tuesday. Maxim Group reissued a “hold” rating on shares of bluebird bio in a research report on Monday, December 3rd. Finally, Piper Jaffray Companies downgraded bluebird bio from an “overweight” rating to a “neutral” rating and cut their price objective for the stock from $240.00 to $120.00 in a research report on Thursday. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and seventeen have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $194.80.
Shares of NASDAQ:BLUE opened at $102.23 on Friday. The stock has a market cap of $5.95 billion, a P/E ratio of -13.26 and a beta of 2.37. bluebird bio Inc has a 12-month low of $100.99 and a 12-month high of $236.17.
bluebird bio (NASDAQ:BLUE) last announced its earnings results on Thursday, November 1st. The biotechnology company reported ($2.73) EPS for the quarter, beating analysts’ consensus estimates of ($2.90) by $0.17. bluebird bio had a negative return on equity of 31.50% and a negative net margin of 1,326.02%. The company had revenue of $11.50 million during the quarter, compared to analysts’ expectations of $6.90 million. During the same period last year, the business posted ($1.73) EPS. bluebird bio’s revenue for the quarter was up 49.2% on a year-over-year basis. Analysts predict that bluebird bio Inc will post -10.71 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This news story was first posted by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this news story can be accessed at https://www.thelincolnianonline.com/2018/12/08/utah-retirement-systems-buys-800-shares-of-bluebird-bio-inc-blue.html.
About bluebird bio
bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in various clinical studies for the treatment of transfusion- transfusion-dependent ß-thalassemia and severe sickle cell disease.
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.